JG

Jitesh Gordhanbhai Patel

Active Director Director DIN 07821359
DIN 07821359 First appointment Jun 2017 Primary industry Service
Unlock full profile Investments · shareholding · contact details
Current companies 4 active board seats
Past companies 1 historical roles
Total affiliations 5 Since Jun 2017
Shareholding value •••• Premium profile

About Jitesh Gordhanbhai Patel

Data last updated:

Jitesh Gordhanbhai Patel is a Director at Neopath Diagnostics And Research Centre Private Limited (since 2017), Director at Hreedrak Bioscience Private Limited (since 2024) and Director at Jadko Healthcare Private Limited (since 2025), and holds 1 more current directorship. The companies operate in Service and Healthcare. The 2 current companies with reported revenue have a combined latest revenue of ₹1.07 Cr; the largest is Neopath Diagnostics And Research Centre Private Limited at ₹1.04 Cr (FY 2025). Earlier, Jitesh Gordhanbhai Patel was a Partner at Unisn Health And Diagnostics Llp (2022–2024).

DIN 07821359
Primary Designation Director
Industry Service
First Appointment 06 Jun 2017
Oldest Company Age 9 yrs
Largest company Neopath Diagnostics And Research Centre Private Limited · ₹1.04 Cr (FY 2025)
Combined revenue ₹1.07 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director06 Jun 20172017₹1.04 Cr (FY 2025)Active
Hreedrak Bioscience Private Limited U32909GJ2024PTC152460
Director13 Jun 20242024₹3 Lakh (FY 2025)Active
Jadko Healthcare Private Limited U86905GJ2025PTC167592
Director11 Sep 20252025Active
Designated Partner05 Jul 20222022Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Partner11 Mar 20222021Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Neopath Diagnostics And Research Centre Private Limited
Uni & Neo Healthcare And Diagnostics Llp
Jadko Healthcare Private Limited
Hreedrak Bioscience Private Limited
Premium access

Shareholding and investment profile for Jitesh Gordhanbhai Patel

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Jitesh Gordhanbhai Patel

Jitesh Gordhanbhai Patel currently holds 4 directorships: Neopath Diagnostics And Research Centre Private Limited (Director, since 06 Jun 2017, revenue ₹1.04 Cr (FY 2025)); Hreedrak Bioscience Private Limited (Director, since 13 Jun 2024, revenue ₹3 Lakh (FY 2025)); Jadko Healthcare Private Limited (Director, since 11 Sep 2025); Uni & Neo Healthcare And Diagnostics Llp (Designated Partner, since 05 Jul 2022).

Jitesh Gordhanbhai Patel was first appointed on 06 Jun 2017 as Director at Neopath Diagnostics And Research Centre Private Limited. The most recent appointment on record is 11 Sep 2025 at Jadko Healthcare Private Limited.

The 2 current companies of Jitesh Gordhanbhai Patel that report revenue have a combined latest revenue of ₹1.07 Cr: Neopath Diagnostics And Research Centre Private Limited ₹1.04 Cr (FY 2025); Hreedrak Bioscience Private Limited ₹3 Lakh (FY 2025).

Jitesh Gordhanbhai Patel held 1 earlier board appointment: Unisn Health And Diagnostics Llp (Partner, 11 Mar 2022 to 01 Apr 2024).

The current boards of Jitesh Gordhanbhai Patel's companies include Amitaben Jitesh Patel (Neopath Diagnostics And Research Centre Private Limited), Bhaviniben Dharmeshbhai Malsatar (Jadko Healthcare Private Limited), Dharmesh Vishrambhai Malsatar (Jadko Healthcare Private Limited), Mona Samir Gami (Uni & Neo Healthcare And Diagnostics Llp).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available